• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

3.980 +0.010 (+0.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NRX Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
June 05, 2026
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option
June 04, 2026
Offering was led by B Group Capital with significant participation from, among others, Columbia Threadneedle Investments, Corbets Capital, Venture 76, and Mossrock Capital 
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
June 03, 2026
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
June 02, 2026
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026
May 28, 2026
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
First Commercial Deployment of FDA-Cleared Transcranial Magnetic Stimulation (TMS) for Major Depressive Disorder and Other Neurological Conditions: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
May 28, 2026
Via Get News
Topics Government
News headline image
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
May 27, 2026
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 18, 2026
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medicus Pharma
May 16, 2026
Via ACCESS Newswire
News headline image
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update
May 14, 2026
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Clearance for Depression and Suicidality Trial
May 07, 2026
Via Investor Brand Network
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality
May 07, 2026
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
NetworkNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Initiates First Commercial Manufacturing Order For Preservative-Free Ketamine
May 05, 2026
Via Investor Brand Network
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine
May 05, 2026
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
GLOBAL MARKETS SPOTLIGHT: New to The Street Show #748 Delivers High-Impact CEO Interviews and Spotlight TV Commercials Across Bloomberg to 250M+ Households Worldwide
May 01, 2026
Via ACCESS Newswire
News headline image
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global
April 25, 2026
Via ACCESS Newswire
News headline image
Positive FDA Response on Preservative-Free Ketamine After President Trump Orders Accelerated Approval for Psychedelic Medication Developers Including NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
April 22, 2026
Via Get News
Topics Government
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives Positive FDA Review Letter Supporting Ketamine ANDA Progress
April 22, 2026
Via Investor Brand Network
News headline image
NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program
April 22, 2026
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Presidential Executive Order to Accelerate Approval of Psychedelic Medications; Those Being Developed by NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
April 21, 2026
Via Get News
Topics Government
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Supports Executive Order To Accelerate Psychedelic Drug Development
April 20, 2026
Via Investor Brand Network
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality
April 20, 2026
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Military and First Responder Opportunity for Robotic-Enabled Transcranial Magnetic Stimulation via Neuroplastic Therapy from NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
April 15, 2026
Via Get News
DefenseNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Forms NRx Defense Systems Subsidiary to Advance Neuroplastic Therapies for Military and Government Applications
April 15, 2026
Via Investor Brand Network
BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Forms NRx Defense Systems Subsidiary to Advance Neuroplastic Therapies for Military and Government Applications
April 15, 2026
Via Investor Brand Network
News headline image
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications
April 15, 2026
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Appoints First Chief Commercial Officer Ahead of Ketamine Launch
April 13, 2026
Via Investor Brand Network
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer
April 13, 2026
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Labeling Feedback for Preservative-Free Ketamine Application
April 06, 2026
Via Investor Brand Network
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application
April 06, 2026
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap